中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2012年
12期
985-988
,共4页
刘立民%张兴霞%赵广圣%司叶俊%林国强%张彦明%何广胜%吴德沛
劉立民%張興霞%趙廣聖%司葉俊%林國彊%張彥明%何廣勝%吳德沛
류립민%장흥하%조엄골%사협준%림국강%장언명%하엄성%오덕패
白血病,淋巴细胞,急性%Th22细胞%白细胞介素22%转化生长因子
白血病,淋巴細胞,急性%Th22細胞%白細胞介素22%轉化生長因子
백혈병,림파세포,급성%Th22세포%백세포개소22%전화생장인자
Leukemia,lymphoblastic,acute%Th22 cell%Interleukin-22%Transforming growth factors
目的 研究Th22细胞在急性淋巴细胞白血病(ALL)患者外周血中的表达水平,并探讨其意义.方法 用流式细胞术分别检测B系ALL(B-ALL)及T系ALL(T-ALL)初诊患者、完全缓解期患者及正常对照组外周血中Th22细胞所占比例.用酶联免疫吸附实验(ELISA)分别检测各组外周血血清中IL-22、转化生长因子(TGF)-β、TNF-α、IL-6水平.用半定量RT-PCR方法分别检测各组外周血单个核细胞中Th22细胞的相关转录因子IL-22 mRNA的表达水平.并逐层分析比较.结果 初诊B-ALL、T-ALL患者Th22细胞比例,血清IL-22、TNF-α、IL-6水平及单个核细胞IL-22 mRNA的表达水平分别为(0.44±0.10)%、(10.9±3.4)ng/L、(110.7±26.5)ng/L、(60.2±13.8)ng/L、0.17±0.04和(0.46±0.11)%、(11.2±3.5)ng/L、(114.6±27.0)ng/L、(58.7±12.4) ng/L、0.19±0.04;缓解期B-ALL、T-ALL患者分别为(0.59±0.15)%、(14.3±4.1)ng/L、(142.5±32.7)ng/L、(83.7±18.9)ng/L、0.25±0.06和(0.60±0.15)%、(14.6±4.3)ng/L、(140.4±31.4)ng/L、(81.4±18.2) ng/L、0.26±0.06,均明显低于正常对照组的(1.24±0.31)%、(19.7±6.6)ng/L、(238.3±50.4)ng/L、(138.0±27.1)ng/L、0.49±0.09,差异有统计学意义(P<0.01).缓解期B-ALL、T-ALL患者Th22细胞比例,血清IL-22、TNF-α、IL-6水平及单个核细胞IL-22 mRNA的表达水平均高于初诊B-ALL、T-ALL患者,差异有统计学意义(P<0.05).B-ALL与T-ALL比较差异无统计学意义(P>0.05).初诊B-ALL、T-ALL和缓解期B-ALL、T-ALL患者TGF-β水平分别为(30.6±8.2)ng/L、(31.4±8.8)ng/L和(24.2±5.8)ng/L、(25.1±6.1)ng/L,明显高于正常对照组的(9.6±2.8)ng/L,差异有统计学意义(P<0.01),且初诊患者TGF-β水平高于缓解期患者(P<0.05);B-ALL与T-ALL比较差异无统计学意义(P>0.05).结论 ALL患者体内Th22细胞数量减少,可能与ALL的发生发展呈负相关,提示ALL患者体内TNF-α、IL-6的表达减低及TGF-β的过度表达可能抑制Th22细胞的分化发育.
目的 研究Th22細胞在急性淋巴細胞白血病(ALL)患者外週血中的錶達水平,併探討其意義.方法 用流式細胞術分彆檢測B繫ALL(B-ALL)及T繫ALL(T-ALL)初診患者、完全緩解期患者及正常對照組外週血中Th22細胞所佔比例.用酶聯免疫吸附實驗(ELISA)分彆檢測各組外週血血清中IL-22、轉化生長因子(TGF)-β、TNF-α、IL-6水平.用半定量RT-PCR方法分彆檢測各組外週血單箇覈細胞中Th22細胞的相關轉錄因子IL-22 mRNA的錶達水平.併逐層分析比較.結果 初診B-ALL、T-ALL患者Th22細胞比例,血清IL-22、TNF-α、IL-6水平及單箇覈細胞IL-22 mRNA的錶達水平分彆為(0.44±0.10)%、(10.9±3.4)ng/L、(110.7±26.5)ng/L、(60.2±13.8)ng/L、0.17±0.04和(0.46±0.11)%、(11.2±3.5)ng/L、(114.6±27.0)ng/L、(58.7±12.4) ng/L、0.19±0.04;緩解期B-ALL、T-ALL患者分彆為(0.59±0.15)%、(14.3±4.1)ng/L、(142.5±32.7)ng/L、(83.7±18.9)ng/L、0.25±0.06和(0.60±0.15)%、(14.6±4.3)ng/L、(140.4±31.4)ng/L、(81.4±18.2) ng/L、0.26±0.06,均明顯低于正常對照組的(1.24±0.31)%、(19.7±6.6)ng/L、(238.3±50.4)ng/L、(138.0±27.1)ng/L、0.49±0.09,差異有統計學意義(P<0.01).緩解期B-ALL、T-ALL患者Th22細胞比例,血清IL-22、TNF-α、IL-6水平及單箇覈細胞IL-22 mRNA的錶達水平均高于初診B-ALL、T-ALL患者,差異有統計學意義(P<0.05).B-ALL與T-ALL比較差異無統計學意義(P>0.05).初診B-ALL、T-ALL和緩解期B-ALL、T-ALL患者TGF-β水平分彆為(30.6±8.2)ng/L、(31.4±8.8)ng/L和(24.2±5.8)ng/L、(25.1±6.1)ng/L,明顯高于正常對照組的(9.6±2.8)ng/L,差異有統計學意義(P<0.01),且初診患者TGF-β水平高于緩解期患者(P<0.05);B-ALL與T-ALL比較差異無統計學意義(P>0.05).結論 ALL患者體內Th22細胞數量減少,可能與ALL的髮生髮展呈負相關,提示ALL患者體內TNF-α、IL-6的錶達減低及TGF-β的過度錶達可能抑製Th22細胞的分化髮育.
목적 연구Th22세포재급성림파세포백혈병(ALL)환자외주혈중적표체수평,병탐토기의의.방법 용류식세포술분별검측B계ALL(B-ALL)급T계ALL(T-ALL)초진환자、완전완해기환자급정상대조조외주혈중Th22세포소점비례.용매련면역흡부실험(ELISA)분별검측각조외주혈혈청중IL-22、전화생장인자(TGF)-β、TNF-α、IL-6수평.용반정량RT-PCR방법분별검측각조외주혈단개핵세포중Th22세포적상관전록인자IL-22 mRNA적표체수평.병축층분석비교.결과 초진B-ALL、T-ALL환자Th22세포비례,혈청IL-22、TNF-α、IL-6수평급단개핵세포IL-22 mRNA적표체수평분별위(0.44±0.10)%、(10.9±3.4)ng/L、(110.7±26.5)ng/L、(60.2±13.8)ng/L、0.17±0.04화(0.46±0.11)%、(11.2±3.5)ng/L、(114.6±27.0)ng/L、(58.7±12.4) ng/L、0.19±0.04;완해기B-ALL、T-ALL환자분별위(0.59±0.15)%、(14.3±4.1)ng/L、(142.5±32.7)ng/L、(83.7±18.9)ng/L、0.25±0.06화(0.60±0.15)%、(14.6±4.3)ng/L、(140.4±31.4)ng/L、(81.4±18.2) ng/L、0.26±0.06,균명현저우정상대조조적(1.24±0.31)%、(19.7±6.6)ng/L、(238.3±50.4)ng/L、(138.0±27.1)ng/L、0.49±0.09,차이유통계학의의(P<0.01).완해기B-ALL、T-ALL환자Th22세포비례,혈청IL-22、TNF-α、IL-6수평급단개핵세포IL-22 mRNA적표체수평균고우초진B-ALL、T-ALL환자,차이유통계학의의(P<0.05).B-ALL여T-ALL비교차이무통계학의의(P>0.05).초진B-ALL、T-ALL화완해기B-ALL、T-ALL환자TGF-β수평분별위(30.6±8.2)ng/L、(31.4±8.8)ng/L화(24.2±5.8)ng/L、(25.1±6.1)ng/L,명현고우정상대조조적(9.6±2.8)ng/L,차이유통계학의의(P<0.01),차초진환자TGF-β수평고우완해기환자(P<0.05);B-ALL여T-ALL비교차이무통계학의의(P>0.05).결론 ALL환자체내Th22세포수량감소,가능여ALL적발생발전정부상관,제시ALL환자체내TNF-α、IL-6적표체감저급TGF-β적과도표체가능억제Th22세포적분화발육.
Objective To investigate the proportion of Th22 cells in peripheral blood of patients with acute lymphoblastic leukemia (ALL) and evaluate its significance.Methods The proportions of Th22 cells in peripheral blood of B-ALL and T-ALL patients before therapy (group 1), B-ALL and T-ALL patients in complete remission (ALL-CR, group 2) and healthy donors (group 3) were evaluated by flow cytometry. The cytokines IL-22, TGF-β, TNF-α and IL-6 in peripheral blood of each group were measured by enzyme-linked immunosorbent assay (ELISA). The levels of IL-22 mRNA in peripheral blood mononuclear cells of each group were examined by reverse transcription-PCR (RT-PCR). Results The percentages of Th22 cells and the levels of IL-22, TNF-α, IL-6 and IL-22 mRNA in B-ALL and T-ALL patients before therapy were (0.44±0.10)%,(10.9±3.4)ng/L,(110.7±26.5)ng/L,(60.2±13.8)ng/L, 0.17±0.04 and (0.46±0.11)%,(11.2±3.5)ng/L,(114.6±27.0)ng/L,(58.7±12.4)ng/L,0.19±0.04, respectively; Which in B-ALL and T-ALL patients in complete remission were(0.59±0.15)%,(14.3±4.1)ng/L,(142.5±32.7)ng/L,(83.7±18.9)ng/L,0.25±0.06 and(0.60±0.15)%,(14.6±4.3)ng/L,(140.4±31.4)ng/L,(81.4±18.2) ng/L, 0.26±0.06, significantly lower than those in healthy donors [(1.24±0.31)%,(19.7±6.6)ng/L,(238.3±50.4)ng/L,(138.0±27.1)ng/L,0.49±0.09] (P<0.01). The percentages of Th22 cells and the levels of IL-22, TNF-α, IL-6 and IL-22 mRNA in group l were lower than those in group 2 (P<0.05), there was not significant difference between B-ALL and T-ALL (P＞0.05). But the levels of TGF-β in B-ALL and T-ALL patients before therapy [(30.6±8.2)ng/L,(31.4±8.8)ng/L] and in complete remission [(24.2±5.8)ng/L,(25.1±6.1)ng/L] were significantly higher than those in group 3[(9.6±2.8)ng/L](P<0.01). However,the level of TGF-β in group 1 was higher than that of group 2 (P<0.05), there was not significant difference between B-ALL and T-ALL (P＞0.05).Conclusion Both the number and function of Th22 cells reduced in ALL patients. Th22 cells might be negatively correlated with ALL progression. The lower levels of TNF-α and IL-6, and overexpression of TGF-β in ALL patients might suppress the differentiation of Th22 cells.
